SCHEMBL5577643

SCHEMBL5577643

COc1ccc(CN2CCN(c3cccc(CNC(=O)c4ccccc4C)c3)CC2)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 2/20 0.52
LMNA P02545 6/20 0.49
HPGD P15428 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 2/20 0.49
CCR3 P51677 2/20 0.49
USP2 O75604 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
THRB P10828 1/20 0.46
PDE5A O76074 2/20 0.46
GFER P55789 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5577506 0.92 CHRM3 (0.54) CHRM3LMNAHPGDSMN1; SMN2MAPT
SCHEMBL5577814 0.88 HSD17B10 (0.55) CHRM3LMNAHPGDSMN1; SMN2MAPT
SCHEMBL5577716 0.88 LMNA (0.56) CHRM3LMNAHPGDSMN1; SMN2MAPT
SCHEMBL5577377 0.87 LMNA (0.53) CHRM3LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL5577821 0.87 POLB (0.55) CHRM3MAPTTSHRMAPK1DRD2
SCHEMBL5577598 0.85 LMNA (0.54) CHRM3LMNAALDH1A1DRD2DRD3
SCHEMBL5577625 0.84 LMNA (0.61) CHRM3LMNAHPGDSMN1; SMN2MAPT
SCHEMBL5577326 0.83 LMNA (0.52) CHRM3LMNAHPGDSMN1; SMN2MAPT
SCHEMBL5577677 0.83 SMN1; SMN2 (0.54) CHRM3LMNAHPGDSMN1; SMN2MAPT
SCHEMBL5577637 0.83 TSHR (0.49) CHRM3LMNAHPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-22 US disclosed
EP-1616862-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043079-A1 Heterocyclic compound containing nitrogen atom and use thereof HLA-DRB1, MIF, HLA-C CHRM3 2099/4885LMNA 4819/4885HPGD 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.